Determination of the Effectiveness of Oral Chlorine Dioxide in the Treatment of COVID 19

ClinicalTrials.gov Identifier: NCT04343742

Recruitment Status : Recruiting
First Posted : April 13, 2020
Last Update Posted : May 27, 2020

See **Contacts and Locations**

Sponsor:
Genesis Foundation

Information provided by (Responsible Party):
Eduardo Insignares Carrione, Genesis Foundation

Study Description

Go to

Brief Summary:

Abstract The objective of this study is to review, through prospective case research, the efficacy of oral chlorine dioxide in the treatment of patients with COVID infection 19. The research will be carried out between April and June 2020 with a quasi-experimental design in two health care centers on a sample of twenty (20) patients, through direct

intervention, who will measure the changes in the manifest symptoms of infection and negativity. a COVID 19 after administration of the study preparation, to determine the effectiveness of chlorine dioxide in the treated group.

Based on the results that are found and on the evaluation of efficacy on the basis of clinical improvement on a scale of 1 to 5, and of the negativization of COVID 19, we can conclude whether the therapeutic efficacy in this investigation is considered good by verifying whether or not there is efficacy of treatment with chlorine dioxide in COVID 19.

With this research, it is hoped to stimulate the search for new therapeutic options in the treatment of COVID 19 and contribute to the development of NEW options in medications, considering the immense number of deaths and morbidity that currently exists in the present pandemic.

Key words: COVID 19, chlorine dioxide, treatment.

Condition or disease	Intervention/treatment
COVID-19	Drug: chlorine dioxide 3000 ppm

▶ Show detailed description

Study Design

Go to

Study Type :
Observational

Estimated Enrollment :
20 participants

Observational Model:
Case-Only

Time Perspective:
Prospective

Official Title:
Determination of the Effectiveness of Oral Chlorine Dioxide in the Treatment of COVID 19

Actual Study Start Date :
April 1, 2020

Actual Primary Completion Date :
April 7, 2020

Estimated Study Completion Date :
June 1, 2020

Resource links provided by the National Library of Medicine

Drug Information available for: Chlorine Chlorine dioxide

U.S. FDA Resources

Groups and Cohorts

Go to

Group/Cohort	Intervention/treatment
chlorine dioxide 3000 ppm. Bottle x 150 cc. Assignment of study medication Each patient will receive, in order of admission to the study, a consecutive patient number and the corresponding study medication. The assignment of this medication was made before the start of the study, using a computer generated list. Patients will receive the 3,000 ppm chlorine dioxide base preparation with written and precise instructions on how to prepare and take the dilutions. 7.1 Dosage and route of administration. Medication: chlorine dioxide 3000 ppm. Fco x 150 cc. 10 ml of 3000 ppm chlorine dioxide are added to 1 liter of water, per day. One part is taken every hour, until the content of the bottle is finished (8 to 12 shots). Both the original dioxide bottle and the preparation for the day should be kept refrigerated.	Drug: chlorine dioxide 3000 ppm Each patient will receive the 3,000 ppm chlorine dioxide base preparation with written and precise instructions on how to prepare and take the dilutions. : 10 ml of 3000 ppm chlorine dioxide are added to 1 liter of water, per day. One part is taken every hour, until the content of the bottle is finished (8 to 12 shots).

Outcome Measures

Go to

Primary Outcome Measures :

1. negative testing of covid19 [Time Frame: 7 DAYS]

   amplification of coronavirus genes by RT-PCR

Eligibility Criteria

Go to

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:

Child, Adult, Older Adult

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

No

Sampling Method:

Probability Sample

Study Population

The population to which the study was directed consisted of a group of patients of medical and health profession with active infection with COVID-19, from various medical care centers, hospitals, in the city of Bogotá, Colombia and Madrid, Spain (multicenter .) The selection of the patients was made based on the self-proposal of the doctors / patients as candidates for research, which refers to the fact that they proposed themselves as cases. Similarly, simultaneity was applied, which means that the patients were obtained in the same period of time in which the cases arose.

Criteria

Inclusion Criteria:

- to. Covid 19 positives b. Some of the characteristic symptoms of covid 19: fever, odynophagia, respiratory distress.

c. Age between 18 years and 80 years

Criteria Exclusion:

- to. Covid 19 negatives b. Kidney failure IV / VI. c. Congestive heart failure. d. Patients taking anticoagulants, particularly warfarin sodium

Contacts and Locations

Go to

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): ***NCT04343742***

Contacts

Contact: EDUARDO INSIGNARES-CARRIONE, Research Direc. +573007191994 eduardoinsignarescarrione@gmail.co

Contact: BLANCA BOLANO, researcherer +573107970227 blancambolanog@hotmail.com

Locations

Colombia

Hospital Fhsj **Recruiting**

Bogota, Cundinamarca, Colombia

Contact: YOHANY ANDRADE 3012629694 yohannyandrade2@gmail.com

San Carlos Hospital **Recruiting**

Bogota, Cundinamarca, Colombia

Contact: YOHANNY ANDRADE, INVESTIGATOR +573012629694 yohanny.andrade2@gmail.com

Sponsors and Collaborators

Genesis Foundation

Investigators

Study Chair: yohanny andrade, researcher Genesis Foundation

Study Chair: oswaldo leyva, researcher Genesis Foundation

More Information

Go to

Publications of Results:

Zhu Z, Guo Y, Yu P, Wang X, Zhang X, Dong W, Liu X, Guo C. Chlorine dioxide inhibits the replication of porcine reproductive and respiratory syndrome virus by blocking viral attachment. Infect Genet Evol. 2019 Jan;67:78-87. doi: 10.1016/j.meegid.2018.11.002. Epub 2018 Nov 3.

Other Publications:

Schijven J, Teunis P, Suylen T, Ketelaars H, Hornstra L, Rutjes S. QMRA of adenovirus in drinking water at a drinking water treatment plant using UV and chlorine dioxide disinfection. Water Res. 2019 Jul 1;158:34-45. doi: 10.1016/j.watres.2019.03.090. Epub 2019 Apr 1.

Kingsley DH, Pérez-Pérez RE, Niemira BA, Fan X. Evaluation of gaseous chlorine dioxide for the inactivation of Tulane virus on blueberries. Int J Food Microbiol. 2018 May 20;273:28-32. doi: 10.1016/j.ijfoodmicro.2018.01.024. Epub 2018

Feb 1.

Montazeri N, Manuel C, Moorman E, Khatiwada JR, Williams LL, Jaykus LA. Virucidal Activity of Fogged Chlorine Dioxide- and Hydrogen Peroxide-Based Disinfectants against Human Norovirus and Its Surrogate, Feline Calicivirus, on Hard-to-Reach Surfaces. Front Microbiol. 2017 Jun 8;8:1031. doi: 10.3389/fmicb.2017.01031. eCollection 2017.

Ma JW, Huang BS, Hsu CW, Peng CW, Cheng ML, Kao JY, Way TD, Yin HC, Wang SS. Efficacy and Safety Evaluation of a Chlorine Dioxide Solution. Int J Environ Res Public Health. 2017 Mar 22;14(3). pii: E329. doi: 10.3390/ijerph14030329.

Responsible Party:

Eduardo Insignares Carrione, research director, Genesis Foundation

ClinicalTrials.gov Identifier:

NCT04343742 History of Changes

Other Study ID Numbers:

Genesis AKCOVID- FG-1

First Posted:

April 13, 2020 Key Record Dates

Last Update Posted:

May 27, 2020

Last Verified:

May 2020

Individual Participant Data (IPD) Sharing Statement:

Plan to Share IPD:

Undecided

Studies a U.S. FDA-regulated Drug Product:

No

Studies a U.S. FDA-regulated Device Product:

No

Additional relevant MeSH terms:

Chlorine dioxide

Dental Disinfectants

Disinfectants

Anti-Infective Agents